| |
|
|
|
| deaths (OS) | progression or deaths (PFS) | RFS/DFS |
laHNSCC - 1st line (L1) locally advanced (laHNSCC) laHNSCC - 1st line (L1) |
|
| avelumab alone vs. placebo | 1 | | | - |
mHNSCC - L1 - all population metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 1st line (L1) mHNSCC - L1 - all population |
|
| pembrolizumab alone vs. cetuximab plus platin plus 5FU | 1 | | | - |
| pembrolizumab plus 5FU plus platin vs. cetuximab plus platin plus 5FU | 1 | | | - |
mHNSCC - L1 - PDL1 positive metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 1st line (L1) mHNSCC - L1 - PDL1 positive |
|
| pembrolizumab alone vs. cetuximab plus platin plus 5FU | 2 | | | - |
| pembrolizumab plus 5FU plus platin vs. cetuximab plus platin plus 5FU | 2 | | | - |
mHNSCC - L2 - all population metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - all population |
|
| durvalumab alone vs. Standard of Care (SoC) | 1 | | | - |
| nivolumab alone vs. Standard of Care (SoC) | 1 | | | - |
| pembrolizumab alone vs. Standard of Care (SoC) | 1 | | | - |
mHNSCC - L2 - PDL1 negative metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - PDL1 negative |
mHNSCC - L2 - PDL1 positive metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - PDL1 positive |
|
| pembrolizumab alone vs. Standard of Care (SoC) | 1 | | | - |
